SOLARA
Solara Active Pharma Sciences Limited (SOLARA) Stock Analysis
Solara Active Pharma Sciences Limited manufactures active pharmaceutical ingredients and formulations for global generics markets. It supplies APIs across therapeutic areas with USFDA-approved facilities in India. The company was formed from the demerger of Aurobindo's API business. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹696.70
+8.12% 1W | +9.60% 52W
Market Cap
3.4k CR
P/E Ratio
–
52W High
₹774
52W Low
₹422
Div. Yield
0%
Beta
0.9
50 DMA
₹654.2
200 DMA
₹549.3
Profit Margin
-0.1%
Inst. Own.
16.6%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 425 | 212 | 299 | 363 | 347 | 300 | 273 | 319 | 314 | 349 | 387 | 382 | 417 |
| Expenses | 388 | 374 | 290 | 322 | 286 | 243 | 228 | 262 | 279 | 312 | 330 | 320 | 340 |
| Operating Profit | 38 | -162 | 10 | 42 | 61 | 58 | 45 | 57 | 35 | 37 | 58 | 62 | 77 |
| OPM % | 9% | -76% | 3.3% | 12% | 18% | 19% | 17% | 18% | 11% | 11% | 15% | 16% | 18% |
| Other Income | -4 | -62 | -120 | 1 | 0 | 1 | 6 | 1 | 0 | -7 | 6 | 3 | -4 |
| Interest | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 | 21 | 22 | 28 | 22 | 18 |
| Depreciation | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 26 | 26 | 27 | 27 |
| Profit before tax | -17 | -275 | -167 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 | 28 |
| Tax % | 0% | 0% | 53% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -17 | -275 | -255 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 | 28 |
| EPS in Rs | -3.58 | -57.36 | -53.20 | -3.74 | 2.22 | 2.24 | -0.58 | 2.91 | -2.79 | -4.82 | 2.65 | 3.38 | 5.86 |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 | 1,535 |
| Expenses | 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | 1,182 | 1,301 |
| Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 | 187 | 234 |
| OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 16% | 14% | 15% |
| Other Income | 2 | 12 | 27 | 29 | 16 | 22 | -185 | 8 | 0 | -2 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 95 | 89 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 100 | 105 |
| Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -488 | 1 | -7 | 37 |
| Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | 0% | 0% | |
| Net Profit | 0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | -7 | 37 |
| EPS in Rs | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -118.21 | 0.15 | -2.05 | 7.07 | |
| Dividend Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | -2.0% | -3.0% | – |
| Profit CAGR | 25.0% | – | – |
Shareholding Pattern
Promoters42.01%
FIIs14.25%
DIIs2.62%
Public41.10%
Promoters42.01%
FIIs13.58%
DIIs2.69%
Public41.71%
Promoters42.00%
FIIs11.98%
DIIs3.64%
Public42.37%
Promoters42.00%
FIIs11.59%
DIIs3.75%
Public42.66%
Promoters41.93%
FIIs11.52%
DIIs3.74%
Public42.79%
Promoters40.98%
FIIs19.30%
DIIs2.75%
Public36.95%
Promoters30.49%
FIIs15.80%
DIIs2.97%
Public50.73%
Promoters37.94%
FIIs14.63%
DIIs2.61%
Public44.82%
Promoters42.00%
FIIs11.59%
DIIs3.75%
Public42.66%
Promoters41.93%
FIIs11.52%
DIIs3.74%
Public42.79%
SOLARA
Holdings Analysis
Key strengths & risk signals
53
Overall
28
Fundamental
78
Technical
Risks (2)
Cannot calculate PEG - insufficient growth data.
POSITIVE YEAR! Stock gained 9.6% in the last year.
Strengths (3)
BULLISH TREND! 50-day average (654.2) is above 200-day average (549.3) - positive signal.
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 937,209 vs down days: 304,480. Ratio: 3.08x
STRONG POSITION! Current price (696.7) is above both moving averages.
Fundamental & Technical Analysis
53Overall
28Fundamental
78Technical
Fundamental Breakdown
Growth Quality
4/30
Revenue CAGR: -1.2% (DECLINING, 2/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! -0.1% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 43.16% public ownership - higher volatility risk.
Stability Index
4/10
CAREFUL! Company does not have stable profit track. 2 loss-making quarters detected.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (654.2) is above 200-day average (549.3) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (696.7) is above both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
4/10
POSITIVE YEAR! Stock gained 9.6% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 937,209 vs down days: 304,480. Ratio: 3.08x
RSI
3/5
NEUTRAL! RSI at 54.8 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 78.0% of 52W range - positive territory.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - 8.1% (1 week), -2.1% (1 month), 22.1% (3 months).
Beta
4/5
BELOW MARKET! Beta of 0.90 - slightly less volatile than market.
SOLARA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-07-29 | Concall PDF | |
| Q3FY262026-02-10 | Concall PDF | |
| Q2FY262025-11-11 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLARA | ₹696.70 | – | -0.1% | -1.2% | – | +9.6% | 53 | BREAKDOWN | +55.2% | +69.8% | +19.5% | -1.5% |
| INDSWFTLAB | ₹359.20 | 53.7 | 8.5% | -19.7% | -3.2% | +253.4% | 56 | BREAKDOWN | +180.7% | +63.6% | +21.0% | +12.8% |
| UNICHEMLAB | ₹510.60 | 11.8 | 13.2% | 18.4% | – | +10.7% | 63 | BREAKDOWN | -495.2% | +280.7% | +20.1% | +10.0% |
| AARTIDRUGS | ₹396.40 | 18.9 | 7.1% | -2.3% | 5.4% | -22.6% | 53 | BREAKDOWN | -6.9% | -9.1% | +19.0% | -2.4% |
| GUFICBIO | ₹404.50 | 56.4 | 7.5% | 6.1% | -6.9% | +16.2% | 55 | BREAKDOWN | +70.2% | +1.8% | +16.6% | +3.6% |
| HIKAL | ₹215.60 | – | -1.9% | -5.4% | – | -9.8% | 53 | BREAKDOWN | -67.0% | -151.4% | +7.7% | -22.7% |
| INDOCO | ₹245.70 | 767.7 | 0.3% | 3.0% | – | -15.5% | 58 | BREAKDOWN | -281.6% | -400.9% | +8.2% | +2.3% |
| VENUSREM | ₹1,719.50 | 22.4 | 13.4% | 11.6% | 57.0% | +264.9% | 74 | BREAKDOWN | +126.2% | +85.5% | +31.2% | +43.9% |
Data from TradeAlone · Updated daily
SOLARA News
Solara Active Pharma Sciences Limited (solara) Q2’27: Revenue Surges 33% to INR 4,178 Mn, Ebitda More Than Doubles2026-10-16Solara Active Pharma Sciences Limited (solara) Q1’27 Earnings Update: Base Business Revenues Up 24% Yoy2026-07-23Solara Active Pharma Sciences Limited (NSE: Solara) Q4’26 Earnings Update: Strong Momentum in Base Business Despite Ibuprofen Headwinds2026-05-15
